ACE and atherosclerosis: A B2-specific antagonist, HOE140, also had no effect on atherosclerosis progression in ApoE–/– mice without ACE inhibition (13), most likely because the beneficial NO-generating capacity of endothelial B2 bradykinin receptor stimulation is impaired in atherosclerosis and cardiovascular disease [Figure 8B, (42, 43, 48)].